ESGCT / SETGYC Annual Congress

93 days

0 hours

2 mins

Print Programme
Tuesday 22 October 2019
16:30-19:00 2018 Opening session
Chairs: Hildegard Büning, Fàtima Bosch, Angel Raya

Sponsor: Brammer Bio
INV01: Andrea Ballabio
Tigem, Naples
Title TBC

INV02: Masaio Takahashi
Riken, Kobe
Title TBC
19:00-20:00 Welcome reception
 
Wednesday 23 October 2019
08:30-10:30 Session 1a: Latest news from cardiovascular and pulmonary gene therapy
Chairs: Pilar Sepulveda, Uta Griesenbach

INV03: Mauro Giacca
ICGEB, Trieste 
Title TBC

INV04: Maria Blasco
CNIO, Madrid 
Title TBC

INV05: Seppo Ylä Herttuala
University of Eastern Finland, Kuopio 
Recent developments in cardiovascular gene therapy

2 Oral presentations
Session 1b: Advancement in cancer
Chairs: 
Sponsor: Molmed




INV06: Cristina Fillat
Idibaps, Barcelona
Title TBC

INV07: Chiara Bonini
SR Tiget, Milan
Title TBC

INV08: Vincenzo Cerullo
University of Helsinki
Title TBC


2 Oral presentations
Session 1c: iPSC & organoids, research and therapy developments
Chairs: 




INV09: Nico Lachmann
Hannover Medical School
The „New Stem Cell“: macrophages for disease modeling
and cell based therapies

INV10: Nuria Montserrat
IBEC Barcelona
Title TBCT

INV11: Alfonso Martinez-Arias
University of Cambridge
TBC

2 Oral presentations
Session 1d: Viral vectors manufacturing
Chairs: Eduard Ayuso, Philippe Moullier
Sponsor: Oxford Biomedica

INV12: Richard Snyder
Thermo Fisher Scientific
Viral vector manufacturing and testing

INV13: Matthias Hebben
LogicBio
Title TBC

INV14: Hanna Lesch
Kuopio Center for Gene and Cell Therapy,
Translational research of AAV expressing VEGF-B: large scale manufacturing  process development, analytical development and pre-clinical studies in ischemic porcine model

INV15: Amine Kamen
McGill University
Process Intensification for Manufacturing of Viral Vectors for Cell and Gene Therapy
10:30-11:00 Coffee break
11:00-13:00           Plenary session 2: From Pre-clinical to clinical
Chairs: Juan Bueren, 
Sponsor: Biopharma Excellence
INV12: Steve Brown
IMPC, Harwell
The International Mouse Phenotyping Consortium (IMPC): Delivering a comprehensive catalogue of mammalian gene function and novel pre-clinical models

INV13: Fàtima Bosch
UAB, Barcelona
Title TBC

INV14: Matthew Porteus
Stanford University, CA
Title TBC

INV15: Luigi Naldini
SR Tiget, Milan 
Title TBC
13:00-15:00 Lunch
Poster session I sponsored by Gilead
15:00-17:00 Plenary session 3: Clinical trials
Chairs: TBC
Sponsor: RegenX
INV28: David Williams
Harvard Medical School
Title TBC

INV29: Fulvio Mavilio
Audentes Therapeutics, San Francisco, CA
Title TBC

INV30: Alberto Auricchio
TIGEM, Naples
Gene therapy of mucopolysaccharidosis type VI

INV31: TBC
TBC
Title TBC
17:00-17:30 Coffee break
17:30-19:30 Session 2a: Skeletal, muscle & bone gene and cell therapy
Chairs: Marinee Chuah, Ana Buj Bello
Sponsor: Myocure

INV16: Thierry VandenDriessche
VUB, Brussels
Title TBC

INV17: Pura Muñoz
Universidad Pompeu Fabra, Barcelona
Title TBC

INV18: TBC

2 Oral presentations
Session 2b: First in man
Chairs: TBC

Sponsor: Orchard Therapeutics

INV19: Adrian Thrasher
UCL, London
Evolving haematopoietic stem cell gene therapy

INV20: Alessandro Aiuti
SR Tiget, Milan
Title TBC

INV21: Don Kohn
UCLA,  CA
Title TBC

2 Oral presentations
Session 2c: Next generation engineered T&NK cells
Chairs: TBC
Sponsor: BioNTech

INV22: John Maher
UCL, London
Title TBC

INV23: Pablo Menendez
Josep Carrera Research Center, Barcelona 
Title TBC

INV24: Concetta Quintarelli
Ospedale Bambino Gesù, Roma
TBC

2 Oral presentations
Session 2d: AAV vector development
Chairs: TBC
Sponsor: Lonza



INV25: Hildegard Büning
Hannover Medical School
Title TBC

INV26: Eric Kelsic
Harvard Medical School
Title TBC

INV27: David Schaffer
University of California, Berkeley
Title TBC

2 Oral presentations
 
Thursday 24 October 2019
8:30-10:30 Session 4: Stem cells & clinical trials therapies
Chairs: TBC
Sponsor: Rocket
INV32: Juan Bueren 
CIEMAT CIBERER, Madrid
Title TBC

INV33: Michel Sadelain
Memorial Sloan Kettering Cancer Center, NY
Title TBC

INV34: TBC
TBC
Title TBC

INV35: TBC
TBC
Title TBC
10:30-11:00 Coffee break
11:00-13:00 Presidential symposium
Chairs: Hildegard Büning, Angel Raya
Sponsor: bluebird bio
INV30: Hildegard Büning
Hannover Medical School
Presidential address

INV31: Hans Pieter Kiem
Fred Hutchinson Cancer Research Center, Seattle
Title TBC

INV32: Nathalie Cartier
Human Gene Therapy Outstanding achievement award

TBC
Title TBC

Audentes Young Investigator award
TBC
Title TBC
13:00-14:30 Lunch
Poster session II
14:30-16:30 Session 3a: CNS gene therapy
Chairs: TBC
Sponsor: Sarepta

INV39: Alessandra Biffi
Harvard Medical School, MA
HSC gene therapy for neurometabolic and neurodegenerative disorders

INV40: Steve Goldman
University of Rochester, NY
Title TBC

INV41: Steve Gray


2 Oral presentations
Session 3b: Late breaking
Chairs: TBC


INV42: TBC
TBC
Title TBC
INV43: TBC
INV44: TBC
 
Session 3c: Immune responses to gene therapy
Chairs: TBC

INV45: Percy Knolle
TUM, Munich
Mechanisms of liver tolerance and implication for liver-targeted gene therapy

INV46: Roland Herzog
Indiana University, IN
Immune response mechanisms against AAV vectors

INV47: Anna Kajaste-Rudnitski
SR Tiget, Milan
Title TBC
Session 3d: Blood diseases
Chairs: TBC


INV48: Jose Carlos Segovia Sanz
CIEMAT CIBERER Madrid
Title TBC

INV49: Giuliana Ferrari
SR TIGET Milan
Title TBC




4 Oral presentations
 
16:30-17:00 Coffee break
17:00-19:00 Plenary session 5: Gene editing, immune response, toxicity
Chairs: TBC

INV51:David Liu 
Harvard University, MA
Title TBC

INV52: David Rawlings
University of Seattle, WA
Title TBC

INV53: Jim Wilson
University of Pennsylvania
Safety and efficacy of in vivo editing in primate liver.

INV53: Angelo Lombardo
SR Tiget
Title TBC
20:00 Molecular Mingle
 
Friday 25 October 2019
09:00-10:30 Session 4a: New approaches in gene editing
Chairs: TBC
Sponsor: Editas

INV53: Juan Rodriguez-Madoz
University de Navarra, Pamplona
Genome editing for advanced therapies and disease models of rare metabolic diseases

INV54: Claudio Mussolino
University of Freiburg
Title TBC

2 Oral presentations
 
Session 4b: Eye and ear gene therapy
Chairs: TBC
Sponsor: Adverum


INV55: Robin Ali
UCL, London
Title TBC

INV56: Luk Vandenberghe
Harvard Medical School, MA
AAV discovery for neurosensory indications and beyond.



2 Oral presentations
Session 4c: New delivery systems
Chairs: TBC



INV57: Helmut Hanenberg
University of Duisburg - Essen
Title TBC

INV58: TBC








2 Oral presentations
 
Session 4d: Regulatory session
Chairs: TBC


INV59: TBC
TBC
Title TBC

INV60: TBC

INV61: TBC

INV62: TBC








2 Oral presentations
10:30-11:00 Coffee break
11:00-13:00
Session 5a: Cancer


Chairs: TBC
 

INV63: Juan Fueyo
MD Anderson, Houston, TX
Virus, immunology and gliomas: new paradigms

INV64: Ramon Alemany
ICO, Barcelona
Title TBC

INV65: Mark Kay
Stanford University
Title TBC
Session 5b: How to make gene therapy a clinical reality?'
Chairs: TBC


INV66: TBC
TBC
Title TBC
 
INV67: TBC

INV68: TBC
Session 5c: Liver gene and cell therapy
Chairs: TBC
Sponsor: Intellia

INV69: Federico Mingozzi
Spark Therapeutics, Penn
Title TBC

INV70: Paolo Martini
Moderna Therapeutics, MA
Messenger RNA therapy for Inherited Metabolic Disorders

INV71: Nick Weber
Vivet Therapeutics, Pamplona
Targeting the Liver to Fix the Bile: Opportunities and Challenges in Gene Therapy for Inherited Cholestasis

2 Oral presentations
Session 5d:
Late breaking

Chairs: TBC


INV72: TBC
TBC
Title TBC

INV73: TBC

INV74: TBC
13:00-15:00 SETGYC General Assembly
Lunch
15:00-16:30 Plenary session 6: Challenges for the future
Chairs: TBC
Sponsor: Esteve

INV48:Olivier Rabin
WADA, Montreal
Title TBC

INV49: Carl June
University of Pennsylvania, Philadelphia
Title TBC

INV50: Christiane Woopen
University of Köln
Title TBC

Keynote INV51: Kathy High
Spark Therapeutics, Philadelphia
Title TBC

Closing remarks
16:00-17:00 Closing drinks